Inquiry Basket
Loading ......
Filter By Product Search for
ESR1
ESR1 Full Name
Estrogen Receptor 1
ESR1 Introduction
Estrogen Receptor Alpha, encoded by the ESR1 gene, is a ligand-activated nuclear receptor that plays a central role in estrogen signaling and transcriptional regulation. After binding estrogen, ERα translocates to the nucleus and controls the expression of genes involved in cell growth, differentiation, metabolism, and tissue development. The receptor is highly expressed in estrogen-responsive tissues such as the breast, ovary, uterus, bone, and cardiovascular system, making ESR1 one of the most biologically significant regulators in endocrine physiology. Structurally, ERα contains conserved DNA-binding and ligand-binding domains that coordinate hormone recognition and downstream gene activation, while flexible terminal regions help recruit transcriptional cofactors and signaling complexes. Because ESR1 directly influences cellular proliferation and survival pathways, abnormal receptor activity can rapidly alter tissue homeostasis and disease progression.
ESR1 has become one of the most clinically important molecular targets in hormone-dependent cancers, especially estrogen receptor-positive breast cancer. Under normal physiological conditions, ERα signaling supports controlled tissue growth and hormonal balance, but activating ESR1 mutations can convert the receptor into a constitutively active state that no longer depends on estrogen stimulation. These alterations are strongly associated with endocrine therapy resistance, particularly in metastatic breast cancer treated with aromatase inhibitors or other hormone-targeted therapies. Common hotspot mutations located within the ligand-binding domain can sustain continuous transcriptional activation, promoting tumor survival, disease recurrence, and metastatic progression. In addition to endocrine resistance, emerging mechanistic evidence suggests that mutant ESR1 signaling may also contribute to chemotherapy resistance through activation of multidrug resistance pathways, reducing intracellular accumulation of anticancer agents. Researchers are also investigating how ESR1 alterations reshape the tumor immune microenvironment, including potential interactions with immune checkpoint signaling, which may influence future combination therapy strategies.
Beyond oncology, ESR1 dysfunction is linked to a wide spectrum of reproductive and systemic disorders. ERα signaling is essential for ovarian function, follicular maturation, embryo implantation, and hypothalamic-pituitary regulation, meaning reduced receptor expression or impaired signaling can contribute to infertility and abnormal reproductive outcomes. Certain ESR1 variants have been associated with decreased ERα protein stability and altered estrogen responsiveness, potentially disrupting hormonal regulation even when receptor signaling is only partially affected. Outside reproductive biology, ESR1 also contributes to bone density maintenance, cardiovascular protection, lipid metabolism, and neuroendocrine balance. Impaired estrogen receptor signaling has therefore been implicated in osteoporosis, metabolic disorders, vascular disease, and age-related physiological decline. Due to its broad biological impact and direct relevance to therapeutic response, ESR1 continues to attract major attention in biomarker discovery, targeted drug development, endocrine disease research, and precision medicine applications.
Alternate Names for ESR1
ESR1; estrogen receptor 1; ER; ESR; Era; ESRA; ESTRR; NR3A1; estrogen receptor; ER-alpha; estradiol receptor; estrogen nuclear receptor alpha; estrogen receptor alpha E1-E2-1-2; estrogen receptor alpha E1-N2-E2-1-2; nuclear receptor subfamily 3 group A member 1;
Loading ......
